No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VERV240517P5000
- 0.23
- +0.13+130.00%
15min DelayClose May 9 15:58 ET
0.23High0.23Low
0.23Open0.10Pre Close1 Volume62 Open Interest5.00Strike Price23.00Turnover217.19%IV-25.00%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.23Time Value100Contract SizeAmericanOptions Type-0.1792Delta0.1293Gamma27.65Leverage Ratio-0.0341Theta-0.0003Rho-4.96Eff Leverage0.0024Vega
Intraday
- 5D
- 1D
News
Express News | HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
Verve Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 140.19% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/03/2024 540.51% Stifel $56 → $40 Main
RBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)
Buy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth Potential
Verve Therapeutics' Financial Outlook Threatened by CRISPR Patent Disputes
Express News | Verve Therapeutics Inc : Jefferies Cuts Target Price to $28 From $31
Comments
$Verve Therapeutics(VERV.US$ Verve Therapeutics Announces Dosing Of First Patient In Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
$Verve Therapeutics(VERV.US$ However, the sixth participant treated in the 0.45 mg/kg cohort experienced a Grade 3 drug-induced transient increase in serum alanine aminotransferase (ALT) as well as a serious adverse event of Grade 3 drug-induced thrombocytopenia within the first four days after dosing. The participant did not experience any bleeding or other symptoms related to the laboratory abnormalities, and the abnormalities resolved fully within a few ...
14
Analysts are optimistic about Verve Therapeutics, predicting reduced losses this year, indicating a move towards profitability. Despite expected slower revenue growth, it's still anticipated to outpace the industry. However, concerns like dilutive stock issuance over the past year persist.
Read more